Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model

European Journal of Vascular and Endovascular Surgery

Volumn 15, Issue 6, 1998, Pages 515-520

  Holst, J ^a   Kristensen, A T ^a   Kristensen, H I ^a   Ezban, M ^a   Hedner, U ^a  

^a HELSINGBORG HOSPITAL   (Sweden)

Author keywords

FVIIa; Inactivated FVIIa; Patency; TF; TF FVII dependent coagulation; Venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 7A;

ANIMAL MODEL; ARTICLE; BLOOD CLOTTING TIME; FEMALE; JUGULAR VEIN; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOGENESIS; VEIN THROMBOSIS;

EID: 0031876354     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-5884(98)80112-3     Document Type: Article

References (29)

1. Wilcox JN Smith KM Schwartz SM Gordon D Localisation of tissue factor in the normal vessel wall and in the atherosclerotic plaque Proc Natl Acad Sci U.S.A. 86 1989 2839 2843
2. Petersen LC Valentin S Hedner U Regulation of the extrinsic pathway in health and disease: the role of factor VIIa and tissue factor pathway inhibitor Thromb Res 79 1995 1 47
3. Rapaport SI Rao LVM The tissue factor pathway: how it has become a “prima ballerina” Thromb Haemost 74 1995 7 17
4. Camerer E Kolstø Prydz H Cell biology of tissue factor, the principal initiator of blood coagulation Thromb Res 81 1996 1 41
5. Rao LVM Nordfang O Hoang AD Pendurthi UR Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity Blood 85 1995 121 129
6. Abildgaard U Relative roles of tissue factor pathway inhibitor and antithrombin in the control of thrombogenesis Blood Coag Fibrinol 6 Suppl. 1 1995 45 49
7. Antman EM Hirudin in acute myocardial infarction Circulation 90 1994 1624 1630
8. Harker LA Kelly AB Hanson SR Experimental arterial thrombosis in non-human primates Circulation 83 Suppl. IV 1991 IV
9. Harker LA Hanson SR Kelly AB Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists Thromb Haemost 74 1995 464 472
10. Lindahl AK Nordfang O Wildgoose Kelly AB Laurence K Harker LA Hanson SR Antithrombotic effect of a truncated tissue factor pathway inhibitor (TFPI) in baboons Thromb Haemost 69 1993 742
11. Ragni M Cirillo P Ezban M Scognamiglo A Ravera AM Esposito N Chiariello M Golino P Antithrombotic effects of human active-site blocked factor VIIa in a rabbit model of recurrent arterial thrombosis Circulation 94 1996 I 695
12. Jang Y Guzman LA Lincoff AM Gottsauner-Wolf M Forudi F Hart CE Ellis SG Topol EJ The influence of blockade at specific levels of the coagulation cascade on restenosis in rabbit atherosclerotic femoral artery injury model Circulation 92 1995 3041 3050
13. Harker LA Hanson SR Wilcox JN Kelly AB Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway Haemostasis 26 Suppl. 1 1996 76 82
14. Kirchhofer D Tschopp TB Baumgartner HR Active siteblocked factors VIIa and Ixa differentially inhibit fibrin formation in a human ex vivo thrombosis model Arterioscler Thromb Vasc Biol 15 1995 1098 1106
15. Arnljots B Ezban M Hedner U Prevention of experimental arterterial thrombosis by topical administration of active-inactivated factor VIIa Vasc Surg 25 1997 341 346
16. Thim L Bioern S Christensen M Nicolaisen EM Lund HT Pedersen AH Hedner U Aminoacid sequence and postransitional modifications of human factor VIIa from plasma and transfected baby hamster kidney cells Biochem 27 1988 7785 7793
17. Sørensen BB Persson E Freskgård P-O Kjalke M Ezban M Williams T Rao LVM Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor J Biological Chem 272 1997 11863 11868
18. Peterson J Zucker MB The effect of adenosine monophosphate, arcaine and anti-inflammatory agents on thrombosis and platelet function in rabbits Thromb Diath Haemorrh 23 1970 148 158
19. Björk CG Bergqvist D Esquivel C Nilsson B Rudsvik Y Effects of heparin, low molecular weight heparin analogue on experimental venous thrombosis in the rabbit Acta Chir Scand 150 1984 629 633
20. St Louis Acland RD Microsurgery Practise Manual 1980 58 59
21. 1-161) in experimental venous thrombosis — a comparison with; low molecular weight heparin Thromb Haemost 71 1994 214 219
22. Holst J Lindblad B Nordfang O Østergaard PB Hedner U Does the glycosylation influence the experimental antithrombotic effect of two domain tissue factor pathway inhibitor? Haemostasis 26 1996 23 30
23. Holst J Lindblad B Westerlund G Bregengaard C Ezban M Østergaard PB Nordfang O Hedner U Pharmacokinetics and delayed antithrombotic effect of two domain non-glycosylated Tissue Factor Pathway Inhibitor (TFPI) Thromb Res 81 1996 461 470
24. Mathiasson SE Lindblad B Mätzsch T Holst J Bergqvist D Effect of low molecular weight heparin and their combinations on experimental venous thrombosis in rabbits Thromb Haemost 71 1994 363 365
25. Kristensen AT Ezban M Villumsen A Andreassen H Bregengård C Hedner U Evaluation of a modified nail cuticle bleeding model and the effect of active site inhibited factor VIIa (FVIIai) and heparin on bleeding in this model Blood Coagulation and Fibrinolysis 7 1996 414
26. Holst J Lindblad B Ezban M Hedner U Inactivated FVIIa compared to LMWH in an experimental bleeding model Blood Coagulation and Fibrinolysis 7 1996 386
27. Holst J Lindblad B Bergqvist D Garre K Nielsen H Hedner U Østergaard PB Protamine neutralization of intravenous and subcutaneous LMWH (tinzaparin, Logiparin®). An experimental investigation in healthy volunteers Blood Coagulation and Fibrinolysis 5 1994 795 803
28. Ohman ME Califf RM Topol EJ Candela R Abbottsmith C Ellis S Sigmon KN Kereiakes D George B Stack R Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarcation Circulation 82 1990 781 791
29. Markwardt F Hirudin: The promising antithrombotic agent Cardiovasc Drug Rev 10 1992 211 232